ELEGEN

Elegen is a biotechnology startup with a mission to unlock the promise of synthetic biology through accelerating the Design-Build-Test-Learn cycle. The company is at the forefront of the synthetic biology revolution, leveraging new technologies to enable DNA writing at speed and scale.

Founded in 2017 and headquartered in San Carlos, CA, Elegen operates in the Biotechnology and Health Care industries. The company has recently received a significant $35.00M Series B investment on May 14, 2024, showing strong investor confidence. This round of funding was led by a consortium of top life science investors, including 8VC, AME Cloud Ventures, KdT Ventures, Andreessen Horowitz/a16z, ACVC Partners, Alix Ventures, Digitalis Ventures, Triatomic Capital, Agilent Technologies, and John Ballantyne.

Dr. Matthew Hill, with a PhD from Stanford, leads Elegen and has assembled a team of leading biotechnology scientists and entrepreneurs to drive the company's success. With a focus on pioneering DNA writing technologies, Elegen aims to reprogram biology and create biologic solutions to address some of humanity's greatest challenges. This stealth-mode company is well positioned to make a significant impact in the synthetic biology space.